Fresh analysis suggests that patients who discontinue new slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who end conventional lifestyle regimens.
Research printed in a leading health publication points out that while obese people can lose a large proportion of their total mass while using the jabs, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Users buying such medications should be aware of the potential of fast weight regain when the treatment is stopped," warns lead investigator Dr. Susan Jebb.
That rate of recovery implies a reversion to original mass in about 18 months.
Comparing Therapies
The research, which looked at dozens of trials involving over 9,000 of participants, compared the effects of these new drugs with older methods.
Scientists note that individuals who shed pounds through lifestyle changes alone typically experience a slower weight regain—around 0.1 kg a month—once they finish.
Explaining the Rapid Regain
Doctors propose the mode of action of the jabs explains the amplified rebound.
The injections mimic a body's own chemical called GLP-1, which controls appetite.
"Artificially providing GLP-1 concentrations several times higher than normal may cause the body to generate a reduced amount of its endogenous GLP-1, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this hormone supplement means hunger is uncontrolled, making excessive eating a significant risk."
A Chronic Issue?
Medical guidelines recommend the injections for individuals with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
A number of clinicians say that, due to the likelihood of relapse, the therapy might need to be life-long.
This opinion is supported by pharmaceutical companies, who say that the findings "underscore the chronic character of excess weight," similar to managing diseases like high blood pressure.
User Accounts
Individuals who have stopped the jabs explain a intense resurgence of hunger.
"It was like something flipping and I was suddenly starving," described one woman.
This difficulty is exacerbated if individuals have not established sustainable lifestyle or habit changes during therapy.
Widespread Adoption
Recent estimates suggest that millions of people in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.
- Adoption is greater among females than men.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
In conclusion, experts emphasize that while GLP-1 drugs are effective tools for shedding pounds, they are not a magic solution and maintained weight loss relies on ongoing lifestyle management.
